ACRIN 6673
MULTICENTER FEASIBILITY STUDY OF
PERCUTANEOUS RADIOFREQUENCY
ABLATION OF HEPATOCELLULAR
CARCINOMA IN CIRRHOTIC PATIENTS
Final Report
from Central Review Data
6673 RFA of HCC
• Protocol Team
– Gerald Dodd, III, MD (Principal Investigator)
– Fenghai Duan, PhD (Statistician)
– Damian Dupuy, MD (Radiologist)
– Glenn Halff, MD (Surgical Oncologist)
– David Lu, MD (Radiologist)
– Shahla Masood, MD (Central Pathologist)
–
Anthony Shields, MD, PhD (Oncologist)
6673 RFA of HCC
• ACRIN Staff
–
–
–
–
–
–
–
–
–
–
–
–
Lisa Cimino (Imaging)
Vincent Girardi (Biostatistician)
Jeremy Gorelick (Biostatistician)
Donna Hartfeil (Project Manager)
Benjamin Herman (Biostatistician)
Mary Kelly-Trunan (Regulatory)
Anthony Levering (Imaging)
Robin McCall (Imaging)
Maria Oh, (Protocol Development)
Josephine Schloesser (Regulatory)
Chris Steward (Regulatory)
Tina Taylor (Data Manager)
6673 RFA of HCC
14 Participating Centers
University of Texas, Health Science Center, San Antonio / Gerald Dodd, III, MD
University of California, Los Angeles / David Lu, MD
Rhode Island Hospital / Damian Dupuy, MD
Hospital of the University of Pennsylvania / Aalpen Patel, MD
University of Massachusetts Medical Center, Worcester / Sri Shankar, MD
Cedar Sinai Medical Center / Peter Julien, MD and Frank Moser, MD
Mayo Clinic, Rochester / Matthew Callstrom, MD, PhD
Medical College of Wisconsin / Sean Tutton, MD
University of Wisconsin / Fred Lee, MD
University of Texas, MD Anderson / Kamran Ahrar, MD
University of North Carolina / Robert Dixon, MD
University of Alabama, Birmingham / J. Kevin Smith, MD
Scott and White Clinic and Hospital, Texas / Mark Montgomery, MD
University of California, Davis / John McGahan, MD
6673 RFA of HCC
• Primary study objective:
To estimate the proportion of patients
undergoing solitary or repetitive
percutaneous RFA treatment sessions
whose livers have no identifiable tumor
by CT scan at 18 months following
initiation of therapy
6673 RFA of HCC
• Some secondary study objectives:
– Aim: Effects of tumor size, local recurrence,
remote occurrence, whether or not repeated
RFA, etc. on success rate at 18-month
• Notations:
– Local intrahepatic tumor: tumor was treated
but seen again at the ablated site
– Remote intrehepatic tumor: new tumor was
seen but remote from the ablated site(s).
6673 RFA of HCC
• Enrollment Criteria
– Cirrhosis
– MELD Score < 15
– HCC = 1-3 tumors < 3cm,
or 1 tumor > 3 and < 5cm
– No previous treatment for HCC
6673 RFA of HCC
• Treatment
– Percutaneous radiofrequency ablation
• Ablations permitted from enrollment
through 15th month
• Single vendor RFA unit (Covidien)
• Standardized ablation protocol
6673 RFA of HCC
• Follow-up
– 3 phase CT
• Prior to treatment
• Immediately after ablation
• Every 3-months through 18 months post
ablation
6673 RFA of HCC
• Central review
– To determine the presence/absence of tumor
– Scans were divide into two equal batches
and were reviewed by one of the two central
readers.
– Discrepancy from the local read were
adjudicated by the other central reader.
6673 RFA of HCC
• Results
– 45 Eligible patients enrolled
• 29 men, 16 women
• Average age 61 (range, 40 to 81)
– Number of tumors
• 1 = 39
•2=4
•3=2
6673 RFA of HCC
• Results
– Patient status
• 33 dropped out prior to completion
• 12 patients completed study
6673 RFA of HCC
• Results
– Patient status
• 33 dropped out prior to completion
– 15 were transplanted
– 5 died
– 5 withdrew from the study
– 7 started nonprotocol treatment
– 1 developed an extrahepatic tumor
6673 RFA of HCC
• Results
– Patient status
• 15 were transplanted
–4 had tumor on last CT
»2 had a local tumor
»2 had a remote tumor
–11 had no tumor
6673 RFA of HCC
• Results
– Patient status
• 5 patients died
– 2 had tumor on last CT and was the cause
of death for 2 of those
– 3 had no tumor
• 7 patients had non-protocol treatment
– 7 had tumor on last CT
– 0 had no tumor
6673 RFA of HCC
• Results
– Patient status
• 12 patients completed study
–8 = 1 ablation
–2 = 2 ablations
–2= 3 ablations
6673 RFA of HCC
• Results
– Patient status
• 12 patients completed study
– Tumor status on 18 month CT
» 10 = no tumor at treated sites (83%)
» 8 = tumor free (67%)
» 2 = local intrahepatic tumor (17%)
» 4 = remote intrahepatic tumor (33% )
6673 RFA of HCC
• Results
– Aim: control disease at 18 months
• Out of 45 patients, 8 patients who completed
study without tumor
– success rate = 8/45 (18%)
(95% Exact CI: 0.08, 0.32)
• Only 12 patients who made it to 18 months
– success rate = 8/12 (67%)
(95% Exact CI: 0.35, 0.90)
6673 RFA of HCC
• Results
– Aim: control disease at 18 months or
successful bridge to transplant
• Including the previous 8 tumor-free patients at
18 months plus 15 patients who made it to
transplant
– success rate = 23/45(51%)
(95% Exact CI: 36%, 66%)
6673 RFA of HCC
• Results
Factors
O.R.
95% CI
P value
multiple RFA
44.3
5.36
367.1
0.0004
Tumor size (cm)
0.40
0.18
0.88
0.022
Local tumor
4.54
1.95
10.6
0.0005
Remote tumor
0.02
0.004
0.10
<.0001
Gender (Female)
0.97
0.07
13.3
0.9
Age
1.19
1.03
1.38
0.017
6673 RFA of HCC
• Results
– Local tumor control
• Out of 60 ablated tumors, 36 were never seen
again.
– Local control rate = 36/60 (60%)
(95% Exact CI: 0.47, 0.72)
6673 RFA of HCC
• Results
Kaplan-Meier Estimate of time until a local recurrence
Survival Distribution Function
1.00
0.75
0.50
0.25
Median time to recurrence is 12 months (95%
CI: 6 – 18 months)
0.00
0
5
10
15
20
Months
Legend:
Product-Limit Estimate Curve
Censored Observations
25